UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Annals of oncology, 2014-09, Vol.25 (9), p.1735-1742

2014

Volltextzugriff (PDF)

Modern trends in minimally invasive versus open hepatectomy for colorectal liver metastasis: an analysis of ACS-NSQIP

Surgical endoscopy, 2023-07, Vol.37 (7), p.5591-5602

2023

Volltextzugriff (PDF)

Uneven substrates constrain walking speed in ants through modulation of stride frequency more than stride length

Royal Society open science, 2020-03, Vol.7 (3), p.192068-192068

2020

Volltextzugriff (PDF)

Using the Flipped Classroom Model in Surgical Education: Efficacy and Trainee Perception

Journal of surgical education, 2021-11, Vol.78 (6), p.1803-1807

2021

Volltextzugriff (PDF)

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development

Journal of Cancer, 2017-01, Vol.8 (7), p.1255-1262

2017

Volltextzugriff (PDF)

Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Annals of oncology, 2018-10, Vol.29, p.viii400-viii400

2018

Volltextzugriff (PDF)

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines

Expert review of clinical immunology, 2016-12, Vol.12 (12), p.1347-1357

2016

Volltextzugriff (PDF)

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

Oncotarget, 2017-02, Vol.8 (9), p.15912-15923

2017

Volltextzugriff (PDF)

1128OPre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression

Annals of oncology, 2016-10, Vol.27, p.vi366-vi366

2016

Volltextzugriff (PDF)

Abstract P2-09-09: Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-09-09

2019

Volltextzugriff (PDF)

A historical overview of enhanced bus services in Australian cities: What has been tried, what has worked?

Research in transportation economics, 2016-11, Vol.59, p.11-25

2016

Volltextzugriff (PDF)

Abstract P2-09-01: Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-09-01

2019

Volltextzugriff (PDF)

Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER2 / neu peptide vaccine trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11126-e11126

2011

Volltextzugriff (PDF)

Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.564-564

2011

Volltextzugriff (PDF)

Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/neu-based peptide vaccines

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2542-2542

2010

Volltextzugriff (PDF)

Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.2565-2565

2010

Volltextzugriff (PDF)

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Annals of oncology, 2014-09, Vol.25 (9), p.1735

2014

Volltextzugriff (PDF)

Abstract P6-10-04: Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-10-04

2017

Volltextzugriff (PDF)

Peptide Vaccine Strategies in the Treatment of Cancer

Journal of proteomics & bioinformatics, 2013, Vol.6 (4)

TJ, Vreeland

2013

Volltextzugriff (PDF)

Abstract P2-11-01: Final pre-specified analysis of the phase II trial of the GP2+GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P2-P2-11-01

2016

Volltextzugriff (PDF)

OT3-01-18: Combination Immunotherapy with Trastuzumab and the HER2 Vaccine E75 in Low and Intermediate HER2−Expressing Breast Cancer Patients To Prevent Recurrence

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT3-01-18-OT3-01-18

2011

Volltextzugriff (PDF)

Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-16-02

2012

Volltextzugriff (PDF)

Abstract P2-14-01: Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P2-P2-14-01

2013

Volltextzugriff (PDF)

Abstract P4-13-02: Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-13-02

2013

Volltextzugriff (PDF)

1 – 25 von 3.557

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.157)
Mit Volltextzugriff
(2.902)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(2.322)
Life Sciences & Biomedicine
(1.750)
Humans
(1.237)
Male
(756)
Female
(745)
Biological And Medical Sciences
(672)
Medical Sciences
(498)
Adult
(461)
Animals
(443)
Middle Aged
(430)
Physical Sciences
(344)
Technology
(310)
Aged
(303)
Oncology
(247)
Fundamental And Applied Biological Sciences. Psychology
(212)
Neurosciences & Neurology
(199)
Physics
(197)
Engineering
(195)
Exact Sciences And Technology
(163)
Surgery
(163)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.693)
IngentaConnect
(1.515)
Free E-Journal (出版社公開部分のみ）
(1.347)
Ovid SocietyJournals and Single Titles
(1.181)
NUS Single-Journal Subscriptions
(893)
Elsevier ScienceDirect Journals Complete
(806)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(583)
Wiley Online Library All Journals
(502)
IngentaConnect Journals
(418)
Wiley Online Library Full Collection 2018
(361)
Oxford journals
(223)
SpringerLink_现刊
(188)
JSTOR
(181)
Oxford Journals 2020 Medicine
(168)
IEEE/IET Electronic Library
(120)
Nature_系列刊
(108)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(102)
Taylor & Francis Journals
(101)
Taylor & Francis
(94)
Taylor & Francis Online
(93)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(20)
... seit 30 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Modern trends in minimally invasive versus open hepatectomy for colorectal liver metastasis: an analysis of ACS-NSQIP

Uneven substrates constrain walking speed in ants through modulation of stride frequency more than stride length

Using the Flipped Classroom Model in Surgical Education: Efficacy and Trainee Perception

Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development

Pre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients

1128OPre-specified interim analysis of a randomized phase IIb trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence demonstrates benefit in triple negative (HER2 low-expressing) breast cancer patients

Interim safety analysis of a phase II trial combining trastuzumab and NeuVax, a HER2-targeted peptide vaccine, to prevent breast cancer recurrence in HER2 low expression

Abstract P2-09-09: Initial safety and efficacy of a phase I/IIa trial of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer

A historical overview of enhanced bus services in Australian cities: What has been tried, what has worked?

Abstract P2-09-01: Subgroups analysis of a multicenter, prospective, randomized, blinded phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for prevention of recurrence in breast cancer patients

Monitoring of circulating tumor cell trends in a prospective, randomized, placebo-controlled HER2 / neu peptide vaccine trial

Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone

Assessment of circulating tumor cell (CTC) patterns among disease-free breast cancer patients vaccinated with adjuvant HER2/neu-based peptide vaccines

Effect of a novel II-key hybrid HER2/neu peptide (AE37) vaccine with GM-CSF as compared to GM-CSF alone on levels of regulatory T-cell (Treg) populations

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Abstract P6-10-04: Determining the optimal vaccination strategy using a combination of the folate binding protein (FBP) peptide vaccine (E39+GM-CSF) and an attenuated version (E39') to maximize the immunologic response in breast cancer patients

Peptide Vaccine Strategies in the Treatment of Cancer

Abstract P2-11-01: Final pre-specified analysis of the phase II trial of the GP2+GM-CSF peptide vaccine in high risk breast cancer patients to prevent recurrence

OT3-01-18: Combination Immunotherapy with Trastuzumab and the HER2 Vaccine E75 in Low and Intermediate HER2−Expressing Breast Cancer Patients To Prevent Recurrence

Abstract P5-16-02: Final Results of the Phase I/II Trials of the E75 Adjuvant Breast Cancer Vaccine

Abstract P2-14-01: Breast cancer patients with HER2 low-expression: An under-recognized group at significant risk for recurrence

Abstract P4-13-02: Preliminary results for the phase 1 trial of a dual HER2 peptide cancer vaccine in breast and ovarian cancer patients

Suchergebnisse filtern